PT - JOURNAL ARTICLE AU - Francisco J. PĂ©rez-Reche AU - Ken J. Forbes AU - Norval J. C. Strachan TI - Importance of untested infectious individuals for the suppression of COVID-19 epidemics AID - 10.1101/2020.04.13.20064022 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.13.20064022 4099 - http://medrxiv.org/content/early/2020/04/30/2020.04.13.20064022.short 4100 - http://medrxiv.org/content/early/2020/04/30/2020.04.13.20064022.full AB - The impact of the extent of testing infectious individuals on suppression of COVID-19 is illustrated from the early stages of outbreaks in Germany, the Hubei province of China, Italy, Spain and the UK. The predicted percentage of untested infected individuals depends on the specific outbreak but we found that they typically represent 50% to 80% of the infected individuals. Even when unreported cases are taken into account, we estimate that less than 8% of the population would have been exposed to SARS-CoV-2 by 09/04/2020 in the analysed outbreaks. These levels are far below the 70-85% needed to ensure herd immunity and would predict a resurgence of infection if ongoing lockdowns in the outbreaks are fully lifted. We propose that partially lifted lockdowns together with early and thorough testing allowing for quick isolation of both symptomatic and asymptomatic cases could lead to suppression of secondary waves of COVID-19 epidemics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementN/AAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDetails on data availability are given in the manuscript.